Lovenox/LMWH (medium blue) Unfractionated heparin (orange) Warfarin and variants (navy blue) Other injectable agents (light blue) Other oral agents (beige)
This chart comes from Bayer’s JPM webcast, so it naturally emphasizes the other oral category that includes the jewel of Bayer’s pipeline, Rivaroxaban. Even this forecast of huge uptake for new oral agents shows a substantial pie slice for the other injectable category, which includes such candidates as MNTA’s M118 and GTCB’s ATryn. In my opinion, the other injectable category in 2016 will greatly exceed the $2.4B figure in the chart because there are acute-care indications where injectables will continue to have the edge over oral agents.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.